Rating Change: Diplomat Pharmacy (NYSE:DPLO) Is a Stock Credit Suisse Is Wary of; Firm Downgrades It

November 23, 2016 - By Peter Kolinski

Rating Change: Diplomat Pharmacy (NYSE:DPLO) Is a Stock Credit Suisse Is Wary of; Firm Downgrades It

Diplomat Pharmacy (NYSE:DPLO) Downgrade

In a analysts note revealed today, Credit Suisse decreased shares of Diplomat Pharmacy (NYSE:DPLO) to a “Underperform” rating from a “Neutral” rating.

Diplomat Pharmacy Inc (NYSE:DPLO) Ratings Coverage

Out of 9 analysts covering Diplomat Pharmacy (NYSE:DPLO), 2 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 22% are positive. $55 is the highest target while $17 is the lowest. The $32.43 average target is 125.05% above today’s ($14.41) stock price. Diplomat Pharmacy has been the topic of 16 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The rating was maintained by Cowen & Co on Thursday, November 3 with “Market Perform”. On Tuesday, June 7 the stock rating was maintained by Bank of America with “Neutral”. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) earned “Mkt Perform” rating by Avondale on Thursday, November 3. UBS initiated it with “Buy” rating and $35 target price in Wednesday, October 21 report. As per Wednesday, October 14, the company rating was upgraded by Bank of America. The company was maintained on Tuesday, August 4 by Leerink Swann. The firm has “Mkt Perform” rating by Leerink Swann given on Thursday, November 3. As per Wednesday, October 21, the company rating was maintained by Mizuho. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) has “Market Perform” rating given on Friday, June 24 by Cowen & Co. Mizuho maintained the stock with “Neutral” rating in Wednesday, May 11 report.

About 161,938 shares traded hands. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 52.17% since April 21, 2016 and is downtrending. It has underperformed by 57.50% the S&P500.

Insitutional Activity: The institutional sentiment increased to 1.82 in 2016 Q2. Its up 0.39, from 1.43 in 2016Q1. The ratio increased, as 17 funds sold all Diplomat Pharmacy Inc shares owned while 46 reduced positions. 23 funds bought stakes while 67 increased positions. They now own 50.07 million shares or 2.77% more from 48.72 million shares in 2016Q1.

Essex Inv Mngmt Co Ltd Liability Co reported 15,642 shares or 0.09% of all its holdings. State Of Wisconsin Inv Board accumulated 0.04% or 267,900 shares. First Trust Advsr Limited Partnership last reported 24,398 shares in the company. Nationwide Fund Advsr, a Pennsylvania-based fund reported 59,815 shares. Morgan Stanley accumulated 50,663 shares or 0% of the stock. The Missouri-based Benjamin F Edwards & has invested 0.02% in Diplomat Pharmacy Inc (NYSE:DPLO). Alliancebernstein L P has 0.07% invested in the company for 2.21 million shares. Retirement Systems Of Alabama holds 0.04% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO) for 206,000 shares. Louisiana State Employees Retirement Systems accumulated 0.03% or 16,100 shares. Federated Pa holds 0.05% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO) for 456,300 shares. Price T Rowe Md accumulated 0.04% or 5.57 million shares. Bridgeway Mgmt has 15,400 shares for 0.01% of their US portfolio. Natl Bank Of Montreal Can owns 2,246 shares or 0% of their US portfolio. Moreover, Riverbridge Llc has 0.51% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 704,785 shares. Diam Limited last reported 0.14% of its portfolio in the stock.

Insider Transactions: Since August 1, 2016, the stock had 0 insider buys, and 2 selling transactions for $1.04 million net activity. $440,794 worth of Diplomat Pharmacy Inc (NYSE:DPLO) was sold by Kaddis Atheer A on Monday, August 1.

Diplomat Pharmacy, Inc. operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The company has a market cap of $943.97 million. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. It has a 29.62 P/E ratio. The Firm operates through specialty pharmacy services segment.

According to Zacks Investment Research, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.”

DPLO Company Profile

Diplomat Pharmacy, Inc. (Diplomat), incorporated on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Firm operates through specialty pharmacy services segment. The Firm provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Firm offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).

More notable recent Diplomat Pharmacy Inc (NYSE:DPLO) news were published by: Businesswire.com which released: “DPLO LOSS ALERT: Rosen Law Firm Reminds Diplomat Pharmacy, Inc. Investors of …” on November 17, 2016, also Fool.com with their article: “Why Diplomat Pharmacy, Inc. Is Plunging Today” published on November 03, 2016, Prnewswire.com published: “Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Diplomat Pharmacy …” on November 16, 2016. More interesting news about Diplomat Pharmacy Inc (NYSE:DPLO) were released by: Fool.com and their article: “Why Diplomat Pharmacy, Inc. Shares Are Falling 13.6% Today” published on October 26, 2016 as well as Finance.Yahoo.com‘s news article titled: “Lawsuit for Investors in shares of Diplomat Pharmacy Inc (DPLO) announced by …” with publication date: November 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>